AC 100
Alternative Names: AC-100; Dentonin; DTNLatest Information Update: 02 Oct 2021
At a glance
- Originator Acologix
- Class Osteoporosis therapies; Peptide fragments
- Mechanism of Action Dinoprostone modulators; Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Bone disorders; Cartilage disorders; Periodontal disorders
Highest Development Phases
- Discontinued Bone disorders; Cartilage disorders; Periodontal disorders; Postmenopausal osteoporosis
Most Recent Events
- 06 Mar 2010 AC 100 is still available for licensing (http://www.acologix.com)
- 06 Mar 2010 No development reported - Phase-I for Postmenopausal osteoporosis in USA (SC)
- 06 Mar 2010 Phase-I clinical trials in Bone disorders in USA (SC)